Kliniska studier vid Tema Cancer
–Studier öppna för inklusion inom PO Bäckencancer–
Här visas de studier som är öppna för patientinklusion inom den medicinska enheten (ME). Studierna är uppdelade på de olika patientflödena. Vidare visas ansvarig prövare, forskningssjuksköterska och planerad och aktuell inklusion inom temat (visas ej utanför Karolinska). Listan uppdateras minst en gång i veckan. -Längst ner finns en förklaring till de olika kolumnerna.
Kolorektal cancer
Nr | Namn | Fas |
Startdatum | Ansvarig prövare | Ansvarig forskn.sköt | Plan. |
Akt. |
17/314 |
Watch and wait. Watch and wait-Icke operativ behandling vid strål- och cellgiftsbehandling. |
Ej tillä |
2016-08-08 |
Anna Martling |
Shahrzad Kordnejad |
0 |
132 |
20/038 |
SOULMATE. The Swedish study of liver transplantation for non-resectable/non-ablatable colorectal liver metastases. |
2 |
2021-04-01 |
Mia Karlberg |
Birgitta Nässen |
10 |
0 |
20/073 |
CIM-HIPEC. The native immune system and the development of carcinomatosis among patients with colorectal cance |
Ej tillä |
2020-01-10 |
Caroline Nordenvall |
Madelene Ahlberg |
0 |
139 |
20/074 |
CIM-IBD. Single-cell analysis of intestinal lymphocytes reveals targets for treatment of inflammatory bowel disease |
Ej tillä |
2019-06-13 |
Caroline Nordenvall |
Madelene Ahlberg |
0 |
109 |
20/075 |
CITCCA pilot. CIrculating Tumour DNA in Colorectal CAncer, pilotstudie |
Ej tillä |
2020-10-22 |
Anna Martling |
Madelene Ahlberg |
50 |
109 |
20/076 |
CRUISE. Restorative treatment with ileorectal anastomosis or ileal pouch anal anastomosis in patients with ulcerative colitis |
Ej tillä |
2017-03-01 |
Caroline Nordenvall |
Madelene Ahlberg |
0 |
39 |
20/077 |
EROS. Early intervention and recovery of sexual function in men and women after treatment of rectal cancer–a randomized controlled study with tadalafil compared to standard care |
2-3 |
2020-11-01 |
Christian Buchli |
Hanna Rosén |
50 |
53 |
21/046 |
EFFIPEC. EFFIPEC – Efficacy of Hyperthermic Intraperitoneal ChemotherapySingle-arm Phase I study, followed by an open-label, randomized, controlled registry-based phase III trial |
1 |
2022-10-30 |
Gabriella Palmer |
Birgitta Nässén |
10 |
9 |
21/082 |
Breakwater. An open-label , multicenter , randomized, phase 3 study of first-line encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of encorafenib and cetuximab plus chemotherapy in participants with metastatic BRAF V600E-mutant colorectal cancer |
3 |
2022-06-01 |
Sandra Andersson |
Birgitta Nässén |
0 |
0 |
22/019 |
PelvEx II. Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer |
3 |
2022-08-17 |
Henrik Iversen |
Malin Smedman |
0 |
2 |
Gynekologisk cancer
Nr | Namn | Fas |
Startdatum | Ansvarig prövare | Ansvarig forskn.sköt | Plan. |
Akt. |
18/080 |
RACC. The RACC trial -Robot Assisted Approach to Cervical Cancer |
3 |
2019-05-27 |
Henrik Falconer |
Sara Rydén |
50 |
128 |
19/044 |
SCAN-Mi-studien-cervix. ME |
Ej tillä |
2021-05-01 |
Henrik Falconer |
Perihan Inekci |
100 |
27 |
19/046 |
IPLA-OVCA-lokalanestesi i buken. The effect of local anesthetics on morbidity, start of chemotherapy and mortality in patients undergoing cytoreductive surgery for stage III-IV ovarian cancer. Prospective, randomized, double blind, multicenter study |
3-4 |
2020-08-24 |
Sahar Salehi |
Jenny Johansson |
120 |
148 |
19/058 |
TITANIUM. GestaTIonal TrophoblAstic NeoplasIa assessMent |
4 |
0000-00-00 |
Ulrika Joneborg |
- |
0 |
0 |
21/034 |
DOVACC. A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer |
2-3 |
2023-01-25 |
Josefin Fernebro |
Sara Rydén |
0 |
3 |
21/107 |
GeMore-studien. Genetisk och molekylär kartläggning samt riktad behandling inom gynekologisk cancer |
Ej tillä |
2021-01-02 |
Josefin Fernebro |
Perihan Inekci |
100 |
150 |
21/108 |
ISGA-studien (pre-GAT01). studier av immunsystemet hos patienter med gyncancer |
2021-10-21 |
Emelie Wallin |
Perihan Inekci |
50 |
34 |
|
22/007 |
KEYNOTE C93/ MK3475-C93. A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting |
3 |
2022-11-01 |
Hanna Dahlstrand |
Jenny Johansson |
2 |
1 |
22/069 |
KANDOVA. KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID)of KAND567. An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. |
1-2 |
2023-04-26 |
Hanna Dahlstrand |
Sara Rydén |
0 |
1 |
22/077 |
ct-DNA-studien på cervixcancer. Analys av cell-fritt tumör-DNA i blod. |
Ej tillä |
2022-01-01 |
Kristina Hellman |
Perihan Inekci |
100 |
19 |
23/027 |
iMolE. implementation of Molecular diagnosis of Endometrial cancer |
Ej tillä |
2023-05-23 |
Emelie Wallin |
Perihan Inekci |
0 |
59 |
Prostatacancer
Nr | Namn | Fas |
Startdatum | Ansvarig prövare | Ansvarig forskn.sköt | Plan. |
Akt. |
14/37 |
SPCG-15. Primary radical prostatectomy versus primary radiotherapy for locally advanced prostate cancer: an open randomized clinical trial |
3 |
2014-10-01 |
Mats Olsson |
Jessica Sander |
50 |
59 |
18/034 |
PSMA recidiv-studien. En randomiserad jämförelse mellan konventionell "Salvage" strålbehandling och individualiserad PSMA-pet styrd behandling hos patienter med biokemiskt återfall (PSA) efter prostatacancer operation |
2 |
2018-10-30 |
Stefan Carlsson |
Jessica Sander |
350 |
171 |
18/066 |
ProBio . ProBio: An outcome-adaptive and randomized multi-arm biomarker driven study in patients with metastatic castrate resistant prostate cancer mCRPC) |
2 |
2019-05-27 |
Anders Ullén |
Amanda Hallgren |
20 |
23 |
21/007 |
PSMAddition (CAAA617C12301). An International Prospective Open-label, Randomized, Phase III Study Comparing Androgen Deprivation Therapy and Novel Androgen Axis Drugs Alone or With 177Lu-PSMA-617 in Men with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) |
3 |
2021-12-17 |
Enrique Castellanos |
Jessica Sander |
0 |
6 |
21/023 |
MK3475-365. Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
1-2 |
2022-04-01 |
Enrique Castellanos |
Katarina Hammarlund |
35 |
1 |
21/048 |
PRIS. Prostate Cancer IRE Study (PRIS) – A randomized controlled trial comparing focal to radical treatment in localized prostate cancer |
Ej tillä |
2022-09-07 |
Anna Lantz |
Malin Smedman |
184 |
22 |
Blåscancer
Nr | Namn | Fas |
Startdatum | Ansvarig prövare | Ansvarig forskn.sköt | Plan. |
Akt. |
19/056 |
KEYNOTE 905. A Phase 3 Randomized Study of Cystectomy plus PerioperativePembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with MuscleinvasiveBladder Cancer |
3 |
2019-11-11 |
Anders Ullén |
Katarina Hammarlund |
6 |
12 |
21/041 |
BioBladder. Biomarker profiling to predict response and survival in patients receiving systemic therapy for advanced urothelial cancer |
Ej tillä |
2022-03-10 |
Anders Ullén |
Katrin Fines |
60 |
73 |
21/067 |
RWD Avelumab. A Swedish nationwide real-world data study of maintenanceavelumab in patients with advanced urothelial cancer withoutprogression following first-line platinum-based chemotherapy |
4 |
2022-08-15 |
Anders Ullén |
Faith Jawdat |
0 |
0 |
21/089 |
NORTH-REG Dwell Time Study. NORTH-REG Dwell Time Study |
4 |
2022-04-08 |
Tomas Thiel |
Janelle Cederlund |
20 |
10 |
22/023 |
XNK urotelialcancer. Analys av immunceller från patienter med urotelial cancer i syfte att förbättra immunoterapier |
Ej tillä |
2022-11-21 |
Fernanda Costas Svedman |
Katrin Fines |
10 |
13 |
Njur- och testikelcancer
Nr | Namn | Fas |
Startdatum | Ansvarig prövare | Ansvarig forskn.sköt | Plan. |
Akt. |
14/43 |
ABC-studien. A randomizes phase III study comparing one course of adjuvant Bleomycin,Etoposid and Cisplatin (BEP)and one course of carboplatin AUC7 in clinical stage I seminomatous testicular cancer |
3 |
2015-11-01 |
Gabriella Cohn-Cedermark |
Amanda Hallgren |
150 |
64 |
18/016 |
MIR-Studien . MikroRNA som markörer för monitorering av sjukdomsaktivitet, utvärdering av effekt av cytostatikabehandling, samt verktyg för tidig upptäckt av recidiv av metastatisk testikelcancer. Implentering av MIR-Studien |
Ej tillä |
2019-04-23 |
Anders Kjellman |
Josephine Johansson/Katrin Fines |
250 |
290 |
19/002 |
TINCA II - njurcancer. Det immunologiska landskapet i njurcancer |
Ej tillä |
2021-09-01 |
Ulrika Harmenberg |
Katrin Fines |
100 |
35 |
21/093 |
MK-6482-022. A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab (MK- 3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (6482-022) |
3 |
2023-04-01 |
Fernanda Costa-Svedman |
Helena Forsén |
6 |
3 |
Urologiska sjukdomar
Tyvärr är inga studier aktuella just nu. |
Nr: Forskningsrådets nummer.
Namn: Studiens kortnamn följt av protokollets hela titel.
Fas: Kan vara Fas 1, 2, 3 eller Pilot, kombinationer av dessa, eller Ej tillämpligt.
Startdatum: Vanligen datum för startmöte eller
liknande.
Ansvarig prövare: Den läkare som är ansvarig
för studien inom Tema Cancer.
Ansvarig forskn.sköt: Den forskningssjuksköterska
som är ansvarig.
CKC, Tema Cancer, Karolinska universitetssjukhuset 28.03.2024